Navigation Links
The HER2 paradox: HER2-positive stem cells found in HER2-negative breast cancer
Date:12/14/2012

(SACRAMENTO, Calif.) A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer.

The research, led by Jian Jian Li, director of translational research in the UC Davis Department of Radiation Oncology, examined breast tumors previously thought to lack the HER2 protein, which, when over-expressed, is associated with disease recurrence. Instead, researchers found in the tumors small groups of aggressive, treatment-resistant HER2-positive breast cancer stem cells (BCSCs). The findings will be published Dec. 15 in Clinical Cancer Research.

"These BSCSs are very resistant to traditional treatments, which can lead patients to relapse," said Li, the study lead author. "Despite chemotherapy, radiotherapy or even surgery, the cancer is still recurrent. These findings change our concept of breast cancer because now we know HER2-negative breast cancers can be treated effectively with anti-HER2 treatments."

In the past decade scientists and clinicians have developed a better understanding of how breast cancers differ on the cellular level. Whether a tumor contains HER2, an estrogen receptor protein, a progesterone receptor protein or all three or none can have an enormous impact on the tumor's aggressiveness, the patient's overall prognosis and treatment choices.

HER2-positive breast cancers are routinely treated with drugs that target the HER2 protein, such as Herceptin or Tykerb, with good results. However, until recently, there has been little reason to administer these targeted treatments to patients with HER2-negative cancer.

The team, which included researchers from the University of Michigan Comprehensive Cancer Center, the Holden Comprehensive Cancer Center at the University of Iowa, Emory University School of Medicine and MD Anderson Cancer Center, isolated the HER2-positive BCSCs from irradiated, HER2-negative breast tumors. They also analyzed the stem cells for CD44 and CD24, cell surface proteins that indicate cancer aggressiveness and act as BCSC markers.

The team found that the HER2-positive, CD44 positive, CD24 negative/low BCSCs were more aggressive and highly resistant to radiotherapy. These characteristics were significantly reduced by Herceptin or short interfering RNA. HER2 and CD44 positive BCSCs were found in 57.1 percent of primary tumors and 84.6 percent of recurrent tumors.

In addition to identifying this previously hidden group of HER2-positive stem cells, further examination provided new insights into how these BCSCs maintain their resistance to treatment. A complex network of proteins, including HER2 and STAT3, modulate metastasis, programmed cell death and other functions. As a result, these cells survive the gamut of traditional anti-cancer therapies.

"We feel this research will have a major scientific, as well as clinical, impact," says Li. "We now have a better understanding of how BCSCs resist radiation and other treatments."

While recent research has shown that patients with HER2-negative breast cancer can indeed benefit from HER2 treatments, prior to this work no one understood the mechanisms. This research provides detailed confirmation that HER2 treatment can potentially improve outcomes in HER2-negative breast cancers.

In addition to opening up new treatment options for HER2-negative patients, the research also provides a diagnostic pathway. Markers, such as CD44, could help clinicians identify aggressive, HER2-positive BCSCs in cancers that are ostensibly HER2-negative, individualizing treatment to match each patient's needs. These findings may also advance treatment for other cancers.

"This may open the possibility of treating HER2-positive stem cells in bone, lung or brain cancers, which are all difficult to treat in the later stages," says Li.


'/>"/>

Contact: Dorsey Griffith
dorsey.griffith@ucdmc.ucdavis.edu
916-734-9118
University of California - Davis Health System
Source:Eurekalert

Related medicine news :

1. Mexican paradox: While opinion surveys overestimate abortions 10-fold, abortion mortality clearly decreases
2. TB treatment paradox: Mouse studies show bodys own response helps TB bacteria survive
3. PARP inhibitors may have clinical utility in HER2-positive breast cancers
4. Capturing circulating cancer cells could provide insights into how disease spreads
5. Drug resistant leukemia stem cells may be source of genetic chaos, Temple scientists find
6. Salmonella spreads by targeting cells in our gut, study shows
7. In vitro study finds digested formula, but not breast milk, is toxic to cells
8. To make old skin cells act young again, boost their surroundings, U-M scientists show
9. Temple scientists target DNA repair to eradicate leukemia stem cells
10. Cocktail boosts immune cells in fighting cancer
11. Studying marrow, URMC researchers accelerate blood stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... which come courtesy of leaders in the nursing and health care industry. It also ... and associations—namely Abilene Christian University. , As the nursing industry is coming out ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card ... the country. The nonprofit Hope For Heroes partnered with the leading provider of ... disabled military veterans, as well as police, firemen, and EMS professionals across the country, ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
Breaking Medicine Technology: